Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00474942 |
Apparent mineralocorticoid excess (AME) is a rare inherited disease that can cause severe high blood pressure and low blood potassium in children and adults. It is caused by abnormal hormone metabolism and can be fatal. This study will focus on the genetic basis, natural history, disease progression, and survival of people with AME.
Condition |
---|
Apparent Mineralocorticoid Excess Syndrome |
Study Type: | Observational |
Study Design: | Cohort |
Official Title: | Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol |
Peripheral blood
Estimated Enrollment: | 130 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | November 2013 |
Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
AME is a rare genetic disorder that is caused by a mutated HSD11B2 gene, which encodes the metabolic enzyme 11BHSD2. The altered gene interferes with the ability of 11BHSD2 to inactivate the hormone cortisol. Above-normal cortisol activity then leads to a rise in blood pressure and a reduction of potassium in the blood. It also leads to low levels of the enzyme renin and the hormone aldosterone, both of which are involved in the regulation of long-term blood pressure. Long-term high blood pressure and metabolic defects start at an early age in children with severe AME. In others, AME may start later in life and cause less serious side effects. Symptoms can include poor growth in childhood, delayed puberty, muscle weakness, heart rate irregularity, frequent urination, and thirst. If left untreated, AME can cause serious damage to the eyes, kidneys, heart, and other organs.
Current treatment with the synthetic steroid spironolactone usually improves symptoms; however, despite treatment, some individuals with AME still experience disease progression and even death within years of being diagnosed with AME. Understanding more about AME, how it progresses, and how it affects people differently may help to improve treatment options. The purpose of this study is to examine the genetic basis, natural history, disease progression, and outcome of children and adults with AME. The study will also examine the family members of study participants with AME for any genetic abnormalities and possible mild forms of AME.
This study will last 2 to 7 years. Participants and their family members will attend yearly study visits that will include interviews about medical history, symptoms, and hospital stays; a physical exam; blood pressure testing; and blood and urine collection. Interim reviews of medical records will occur as necessary. Children will undergo an x-ray of the left hand. During the initial study visit, participants will be asked questions about family members and birth size.
Ages Eligible for Study: | up to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Individuals with apparent mineralocorticoid excess plus their family members
Inclusion Criteria for Participants with AME:
Inclusion Criteria for Family Members without Genetic Diagnosis of AME:
Exclusion Criteria for All Participants:
Contact: Claire Gilbert | 212-241-7099 | claire.gilbert@mssm.edu |
United States, New York | |
Mount Sinai School of Medicine | Recruiting |
New York, New York, United States, 10029 | |
Principal Investigator: Maria I. New, MD | |
Principal Investigator: Karen Lin-Su, MD | |
Principal Investigator: Madeleine Harbison, MD | |
Principal Investigator: Robert Wilson, PhD | |
Principal Investigator: Saroj Nimkarn, MD | |
United States, Texas | |
University of Texas Southwestern Medical Center | Not yet recruiting |
Dallas, Texas, United States, 75390 | |
Principal Investigator: Richard J. Auchus, MD, PhD | |
Principal Investigator: Jean D. Wilson, MD | |
Brazil | |
University of Sao Paulo | Not yet recruiting |
Sao Paulo, Brazil, 01060-970 | |
Principal Investigator: Berenice Mendonca, MD | |
Principal Investigator: Ivo Arnhold, MD | |
France | |
University of Lyon | Not yet recruiting |
Lyon, France, 69322 | |
Principal Investigator: Pierre Chatelain, MD | |
Principal Investigator: Maguelone Forest, MD, PhD |
Principal Investigator: | Maria I. New, MD | Mount Sinai School of Medicine |
Responsible Party: | Mount Sinai School of Medicine ( Maria I. New, MD ) |
Study ID Numbers: | RDCRN 5601 |
Study First Received: | May 16, 2007 |
Last Updated: | December 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00474942 |
Health Authority: | United States: Federal Government |
Hypertension Metabolic Alkalosis Hypokalemia |
Apparent mineralocorticoid excess Metabolism, Inborn Errors Metabolic Diseases Genetic Diseases, Inborn Hypokalemia |
Mineralocorticoid Excess Syndrome, Apparent Metabolic disorder Alkalosis Hypertension |
Pathologic Processes Disease Syndrome Steroid Metabolism, Inborn Errors |